Safety and Efficacy of AEB071 and EVEROLIMUS in Patients With CD79-mutant or ABC Subtype Diffuse Large B-Cell Lymphoma
- Conditions
- CD79 Mutant or ABC-subtype Diffuse Large B-Cell Lymphoma
- Interventions
- First Posted Date
- 2013-05-15
- Last Posted Date
- 2020-12-19
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 31
- Registration Number
- NCT01854606
- Locations
- 🇺🇸
Memorial Sloan Kettering Cancer Center Onc. Dept., New York, New York, United States
🇺🇸Washington University School of Medicine Dept of Oncology., Saint Louis, Missouri, United States
🇺🇸Sarah Cannon Research Institute Dept of Onc, Nashville, Tennessee, United States
Study of Efficacy and Safety of Buparlisib (BKM120) Plus Paclitaxel Versus Placebo Plus Paclitaxel in Recurrent or Metastatic Head and Neck Cancer Previously Pre-treated With a Platinum Therapy
- Conditions
- Head and Neck Squamous Cell Carcinoma
- Interventions
- First Posted Date
- 2013-05-13
- Last Posted Date
- 2018-07-24
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 157
- Registration Number
- NCT01852292
- Locations
- 🇺🇸
Dana Farber Cancer Institute IRB, Boston, Massachusetts, United States
🇺🇸University of N.C. at Chapel Hill Lineberger Comp. Cancer Ctr., Chapel Hill, North Carolina, United States
🇬🇧Novartis Investigative Site, Manchester, United Kingdom
Study of Safety of Foradil in Patients With Persistent Asthma
- Conditions
- Persistent Asthma
- Interventions
- First Posted Date
- 2013-05-03
- Last Posted Date
- 2017-03-21
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 827
- Registration Number
- NCT01845025
- Locations
- 🇺🇸
Novartis Investigative Site, Milwaukee, Wisconsin, United States
An Ascending Dose Study to Assess Safety, Tolerability, PK/PD of LHW090 in Healthy Volunteers and in Subjects With Renal Dysfunction
- First Posted Date
- 2013-05-03
- Last Posted Date
- 2020-12-17
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 205
- Registration Number
- NCT01846468
- Locations
- 🇺🇸
Novartis Investigative Site, Knoxville, Tennessee, United States
Visual Outcome in Patients With Symptomatic Macular Polypoidal Choroidal Vasculopathy (PCV) Treated With Either Ranibizumab as Monotherapy or Combined With Verteporfin Photodynamic Therapy (vPDT)
- Conditions
- Polypoidal Choroidal VasculopathyAge-related Macular Degeneration
- Interventions
- First Posted Date
- 2013-05-03
- Last Posted Date
- 2019-06-07
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 321
- Registration Number
- NCT01846273
- Locations
- 🇹🇭
Novartis Investigative Site, Bangkok, Thailand
A Study to Evaluate the Effects of Indacaterol Maleate (QAB149) as a New Formulation in the EPIC Test Fixture
- Conditions
- Asthma
- Interventions
- Other: Placebo Concept 1Drug: QAB149 75 mg Concept 1Drug: QAB149 75 mg Epic Test FixtureOther: Placebo EPIC Test Fixture
- First Posted Date
- 2013-05-03
- Last Posted Date
- 2017-04-20
- Lead Sponsor
- Novartis Pharmaceuticals
- Registration Number
- NCT01845623
To Assess the Efficacy and Safety of Intravitreal Ranibizumab in People With Vision Loss Due to Macular Edema
- First Posted Date
- 2013-05-03
- Last Posted Date
- 2016-05-23
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 181
- Registration Number
- NCT01846299
- Locations
- 🇬🇧
Novartis Investigative Site, Sunderland, United Kingdom
Open Label, Phase II Study to Evaluate Efficacy and Safety of Oral Nilotinib in Philadelphia Positive (Ph+) Chronic Myelogenous Leukemia (CML) Pediatric Patients.
- Conditions
- Philadelphia Positive (Ph+) Chronic Myelogenous Leukemia
- Interventions
- First Posted Date
- 2013-05-01
- Last Posted Date
- 2021-04-22
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 59
- Registration Number
- NCT01844765
- Locations
- 🇺🇸
Loma Linda University Cancer Center, Loma Linda, California, United States
🇺🇸Nationwide Childrens Hospital, Columbus, Ohio, United States
🇺🇸Seattle Childrens Hospital, Seattle, Washington, United States
Ease of Use and Microbial Contamination of Tobramycin Inhalation Powder (TIP) Versus Nebulised Tobramycin Inhalation Solution (TIS) and Nebulised Colistimethate (COLI)
- Conditions
- Cystic Fibrosis
- Interventions
- First Posted Date
- 2013-05-01
- Last Posted Date
- 2016-07-27
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 60
- Registration Number
- NCT01844778
- Locations
- 🇬🇧
Novartis Investigative Site, Newcastle upon Tyne, United Kingdom
12 Month Athena Study: Everolimus vs. Standard Regimen in de Novo Kidney Transplant Patients
- Conditions
- Kidney TransplantationRenal Transplantation
- Interventions
- First Posted Date
- 2013-04-30
- Last Posted Date
- 2017-05-01
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 612
- Registration Number
- NCT01843348
- Locations
- 🇩🇪
Novartis Investigative Site, Tübingen, Germany